Reports Q1 revenue $88.21M, consensus $86.32M. Joseph Capper, MiMedx (MDXG) CEO, commented, “Our solid first quarter 2025 results include total net sales growth of 4% year-over-year and an Adjusted EBITDA margin of 20%. Our Surgical products recorded double-digit growth during the quarter, and we are continuing to see our efforts to build a compelling body of clinical evidence in this space unlock sizable opportunities for our products.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MDXG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MiMedx price target lowered to $15 from $16 at Mizuho
- CMS reviewing coverage policies for skin substitute products
- Northland says MiMedx ‘oversold,’ sees ‘compelling buying opportunity’
- MiMedx Group: Strong Sales Performance and Strategic Positioning Support Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue